(EMAILWIRE.COM, December 08, 2008 ) Accera discovers and develops product breakthroughs in treating central nervous system disorders. Accera’s novel therapeutic approaches positively impact patients with neurodegenerative disorders, who are in need of effective, well-tolerated treatments. Through its proprietary scientific platform, Accera is developing therapies that address metabolic deficiencies by providing an alternative energy source for the brain.

The company’s lead product, Axona, is a first-in-class medical food product for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer’s disease. To be launched in the first quarter of 2009, Axona has been shown in randomized, placebo controlled clinical trials to safely improve cognitive function and memory in patients diagnosed with mild-to-moderate AD. It will be marketed as an adjunctive therapy to currently approved AD drugs and will be administered under physician supervision and dispensed by prescription, in accordance with applicable FDA regulations.

In addition to Axona, Accera is investigating therapeutic treatments for Parkinson's disease, Huntington’s disease and other age-related memory loss disorders. These products, which are based on the company’s proprietary scientific platform, are in early clinical development. As an industry innovator, Accera is committed to improving the care and quality of life of patients with serious and difficult-to-diagnose neurodegenerative diseases.
About 21st Century Health
21st Century Health is independently produced by Multi-Media Productions and is distributed worldwide on CNBC & Fox Business News (as paid programming). The show is an informative magazine style program that exhibits the hottest stories, trends and breakthroughs that will educate and motivate our viewers. For more information, please visit www.21chtv.com

Contact Information:
Multi-Media Productions USA
Selena Hunter
Tel: 5619889449 ext 224
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.